Before the close of the year the Bio Pharma Sector started running wild. It doesn't surprise me why i'm drawn to this company with all the catalysts coming out. Recently with a PT 40 From Roth MKM.
The more you read about the news that comes from this company between CEO investor relations, Merger Deal with Immunogen and entering their phase 3 trial there is so...
This tiny float of 2.3 million shares and market cap of $2.05 million seems to be bottoming out. With news it will explode and fill multiple gaps to the upside. They currently have a drug in clinical trials. Positive results will send this "to the moon."
In the meantime, without news, it is likely to hit $1.40's in the coming days/ weeks. The 52-week high is $81.90!!!
On 5/26/2022 Roth Capital brokerage Lowered the Price Target for First Wave BioPharma, Inc. (FWBI) from $600.00 to $270.00 giving a Buy Rating for the stock!
The stock is now at a historic low: $3.31.
In January 2021 it was $788.
Just to reach the Analyst Price Target, it need to grow 81.5X from this level.
The Market cap is extremely low: 4.58 Mil. 81X would...
First Wave BioPharma is a clinical-stage biopharmaceutical company that specializes in the development of targeted, non-systemic therapies for gastrointestinal diseases.
52 Week Range 1.27 - 26.30
Now the price is close to all time low and looks like a buy opportunity!
James Sapirstein
Chairman, President and CEO of First Wave BioPharma, Inc.:
"We now have development- and clinical-stage programs that span six GI indications with significant market size opportunities, including: COVID-19-related GI infections (estimated at $10 billion, for COVID-19 related anti-virals); ulcerative colitis, ulcerative proctitis and ulcerative...
